Optimization of long-term outcomes for patients with esthesioneuroblastoma

Thomas J. Ow, Ehab Y. Hanna, Dianna B. Roberts, Nicholas B. Levine, Adel K. El-Naggar, David I. Rosenthal, Franco Demonte, Michael E. Kupferman

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Background Esthesioneuroblastoma is a rare cancer of the anterior cranial base that arises in the region of the olfactory rootlets. The purpose of this study was to review the long-term outcomes of patients diagnosed with esthesioneuroblastoma (ENB) treated at a single institution to determine factors associated with improved disease control and survival. Methods A retrospective review of 70 patients with ENB treated at the University of Texas MD Anderson Cancer Center between 1992 and 2007 was undertaken. Survival and recurrence was analyzed and compared using the Kaplan-Meier method and log-rank statistics. Results Seventy patients were reviewed. The majority (77%) had T3 or T4 disease at presentation, 38% identified as modified Kadish stage C or D. Ninety percent of patients received surgical resection as part of their treatment, and 66% received postoperative radiation or chemoradiation. The median follow-up was 91.4 months (7.6 years). Forty-eight percent of patients developed recurrent disease and the median time to recurrence was 6.9 years. Overall and disease-specific median survival was 10.5 and 11.6 years, respectively. Patients who were treated with surgery alone had a median disease-specific survival of 87.9 months, whereas those who were treated with surgery and postoperative radiation had a median disease-specific survival of 218.5 months (p =.047). Conclusion Patients with ENB can achieve favorable long-term survival, even if disease is locally advanced. Survival is improved considerably when surgical resection is followed by postoperative radiation. However, recurrence rates and mortality remain high, and therefore long-term observation in these patients is warranted.

Original languageEnglish (US)
Pages (from-to)524-530
Number of pages7
JournalHead and Neck
Volume36
Issue number4
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Olfactory Esthesioneuroblastoma
Survival
Radiation
Recurrence
Skull Base
Neoplasms
Observation

Keywords

  • esthesioneuroblastoma
  • olfactory
  • operative
  • radiotherapy
  • surgical procedures
  • survival

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Ow, T. J., Hanna, E. Y., Roberts, D. B., Levine, N. B., El-Naggar, A. K., Rosenthal, D. I., ... Kupferman, M. E. (2014). Optimization of long-term outcomes for patients with esthesioneuroblastoma. Head and Neck, 36(4), 524-530. https://doi.org/10.1002/hed.23327

Optimization of long-term outcomes for patients with esthesioneuroblastoma. / Ow, Thomas J.; Hanna, Ehab Y.; Roberts, Dianna B.; Levine, Nicholas B.; El-Naggar, Adel K.; Rosenthal, David I.; Demonte, Franco; Kupferman, Michael E.

In: Head and Neck, Vol. 36, No. 4, 2014, p. 524-530.

Research output: Contribution to journalArticle

Ow, TJ, Hanna, EY, Roberts, DB, Levine, NB, El-Naggar, AK, Rosenthal, DI, Demonte, F & Kupferman, ME 2014, 'Optimization of long-term outcomes for patients with esthesioneuroblastoma', Head and Neck, vol. 36, no. 4, pp. 524-530. https://doi.org/10.1002/hed.23327
Ow TJ, Hanna EY, Roberts DB, Levine NB, El-Naggar AK, Rosenthal DI et al. Optimization of long-term outcomes for patients with esthesioneuroblastoma. Head and Neck. 2014;36(4):524-530. https://doi.org/10.1002/hed.23327
Ow, Thomas J. ; Hanna, Ehab Y. ; Roberts, Dianna B. ; Levine, Nicholas B. ; El-Naggar, Adel K. ; Rosenthal, David I. ; Demonte, Franco ; Kupferman, Michael E. / Optimization of long-term outcomes for patients with esthesioneuroblastoma. In: Head and Neck. 2014 ; Vol. 36, No. 4. pp. 524-530.
@article{dedf5d1864414689a1145d9da01a56d0,
title = "Optimization of long-term outcomes for patients with esthesioneuroblastoma",
abstract = "Background Esthesioneuroblastoma is a rare cancer of the anterior cranial base that arises in the region of the olfactory rootlets. The purpose of this study was to review the long-term outcomes of patients diagnosed with esthesioneuroblastoma (ENB) treated at a single institution to determine factors associated with improved disease control and survival. Methods A retrospective review of 70 patients with ENB treated at the University of Texas MD Anderson Cancer Center between 1992 and 2007 was undertaken. Survival and recurrence was analyzed and compared using the Kaplan-Meier method and log-rank statistics. Results Seventy patients were reviewed. The majority (77{\%}) had T3 or T4 disease at presentation, 38{\%} identified as modified Kadish stage C or D. Ninety percent of patients received surgical resection as part of their treatment, and 66{\%} received postoperative radiation or chemoradiation. The median follow-up was 91.4 months (7.6 years). Forty-eight percent of patients developed recurrent disease and the median time to recurrence was 6.9 years. Overall and disease-specific median survival was 10.5 and 11.6 years, respectively. Patients who were treated with surgery alone had a median disease-specific survival of 87.9 months, whereas those who were treated with surgery and postoperative radiation had a median disease-specific survival of 218.5 months (p =.047). Conclusion Patients with ENB can achieve favorable long-term survival, even if disease is locally advanced. Survival is improved considerably when surgical resection is followed by postoperative radiation. However, recurrence rates and mortality remain high, and therefore long-term observation in these patients is warranted.",
keywords = "esthesioneuroblastoma, olfactory, operative, radiotherapy, surgical procedures, survival",
author = "Ow, {Thomas J.} and Hanna, {Ehab Y.} and Roberts, {Dianna B.} and Levine, {Nicholas B.} and El-Naggar, {Adel K.} and Rosenthal, {David I.} and Franco Demonte and Kupferman, {Michael E.}",
year = "2014",
doi = "10.1002/hed.23327",
language = "English (US)",
volume = "36",
pages = "524--530",
journal = "Head and Neck",
issn = "1043-3074",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Optimization of long-term outcomes for patients with esthesioneuroblastoma

AU - Ow, Thomas J.

AU - Hanna, Ehab Y.

AU - Roberts, Dianna B.

AU - Levine, Nicholas B.

AU - El-Naggar, Adel K.

AU - Rosenthal, David I.

AU - Demonte, Franco

AU - Kupferman, Michael E.

PY - 2014

Y1 - 2014

N2 - Background Esthesioneuroblastoma is a rare cancer of the anterior cranial base that arises in the region of the olfactory rootlets. The purpose of this study was to review the long-term outcomes of patients diagnosed with esthesioneuroblastoma (ENB) treated at a single institution to determine factors associated with improved disease control and survival. Methods A retrospective review of 70 patients with ENB treated at the University of Texas MD Anderson Cancer Center between 1992 and 2007 was undertaken. Survival and recurrence was analyzed and compared using the Kaplan-Meier method and log-rank statistics. Results Seventy patients were reviewed. The majority (77%) had T3 or T4 disease at presentation, 38% identified as modified Kadish stage C or D. Ninety percent of patients received surgical resection as part of their treatment, and 66% received postoperative radiation or chemoradiation. The median follow-up was 91.4 months (7.6 years). Forty-eight percent of patients developed recurrent disease and the median time to recurrence was 6.9 years. Overall and disease-specific median survival was 10.5 and 11.6 years, respectively. Patients who were treated with surgery alone had a median disease-specific survival of 87.9 months, whereas those who were treated with surgery and postoperative radiation had a median disease-specific survival of 218.5 months (p =.047). Conclusion Patients with ENB can achieve favorable long-term survival, even if disease is locally advanced. Survival is improved considerably when surgical resection is followed by postoperative radiation. However, recurrence rates and mortality remain high, and therefore long-term observation in these patients is warranted.

AB - Background Esthesioneuroblastoma is a rare cancer of the anterior cranial base that arises in the region of the olfactory rootlets. The purpose of this study was to review the long-term outcomes of patients diagnosed with esthesioneuroblastoma (ENB) treated at a single institution to determine factors associated with improved disease control and survival. Methods A retrospective review of 70 patients with ENB treated at the University of Texas MD Anderson Cancer Center between 1992 and 2007 was undertaken. Survival and recurrence was analyzed and compared using the Kaplan-Meier method and log-rank statistics. Results Seventy patients were reviewed. The majority (77%) had T3 or T4 disease at presentation, 38% identified as modified Kadish stage C or D. Ninety percent of patients received surgical resection as part of their treatment, and 66% received postoperative radiation or chemoradiation. The median follow-up was 91.4 months (7.6 years). Forty-eight percent of patients developed recurrent disease and the median time to recurrence was 6.9 years. Overall and disease-specific median survival was 10.5 and 11.6 years, respectively. Patients who were treated with surgery alone had a median disease-specific survival of 87.9 months, whereas those who were treated with surgery and postoperative radiation had a median disease-specific survival of 218.5 months (p =.047). Conclusion Patients with ENB can achieve favorable long-term survival, even if disease is locally advanced. Survival is improved considerably when surgical resection is followed by postoperative radiation. However, recurrence rates and mortality remain high, and therefore long-term observation in these patients is warranted.

KW - esthesioneuroblastoma

KW - olfactory

KW - operative

KW - radiotherapy

KW - surgical procedures

KW - survival

UR - http://www.scopus.com/inward/record.url?scp=84896122661&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896122661&partnerID=8YFLogxK

U2 - 10.1002/hed.23327

DO - 10.1002/hed.23327

M3 - Article

C2 - 23780581

AN - SCOPUS:84896122661

VL - 36

SP - 524

EP - 530

JO - Head and Neck

JF - Head and Neck

SN - 1043-3074

IS - 4

ER -